What is it about?
This is our first paper containing some preliminary results from our ongoing Phase II trial (ClinicalTrials.gov: NCT02249013) exploring HIPEC in ovarian cancer.
Featured Image
Why is it important?
Our pioneering all-in-one protocol explores a comprehensive strategy combining perioperative chemotherapy (i.e., NACT plus adjuvant chemotherapy), advanced CRS, fast-track recovery procedures, and a short-course HIPEC for advanced ovarian cancer. Interim analysis suggests low morbidity and lack of impairment of the patient’s QoL with the adoption of this comprehensive treatment involving HIPEC. Our seems to be feasible, safe, and simple for the patient, surgeon, and nursing caregivers.
Perspectives
We hope to add some pieces of evidence to this issue in the near future.
Thales Batista
Read the Original
This page is a summary of: Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach, Cancer Management and Research, December 2017, Dove Medical Press,
DOI: 10.2147/cmar.s153327.
You can read the full text:
Resources
Contributors
The following have contributed to this page
